We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Strong Medicine for Law Breakers - NDRC's First Antitrust Action in the Pharmaceutical Sector under the Anti-Monopoly Law

29 November 2011

On 14 November 2011, China's National Development and Reform Commission (NDRC) announced its decision to sanction the anti-competitive conduct of Shandong Weifang Shuntong Pharmaceutical Co. Ltd. (Shuntong) and Weifang Huaxin Medicine Trading Co. Ltd. (Huaxin).  The fines imposed on the two companies are the highest for antitrust violations under the Anti-Monopoly Law of the People's Republic of China which took effect on 1 August 2008 (AML) so far.  This case is also NDRC's first antitrust action in the pharmaceutical sector under the AML.

The team

Jun Wei

Jun Wei

Office Managing Partner
Beijing

Loading data